Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 50 | 2021 | 5426 | 2.150 |
Why?
|
Lung Neoplasms | 68 | 2023 | 13589 | 1.960 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 51 | 2021 | 11843 | 0.840 |
Why?
|
Small Cell Lung Carcinoma | 9 | 2020 | 451 | 0.830 |
Why?
|
Bronchopulmonary Dysplasia | 4 | 2024 | 329 | 0.680 |
Why?
|
Endpoint Determination | 3 | 2018 | 591 | 0.640 |
Why?
|
Thoracic Neoplasms | 2 | 2020 | 270 | 0.620 |
Why?
|
Clinical Trials as Topic | 20 | 2020 | 8051 | 0.590 |
Why?
|
Data Interpretation, Statistical | 2 | 2018 | 2705 | 0.540 |
Why?
|
Carboplatin | 14 | 2021 | 798 | 0.460 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2014 | 1557 | 0.460 |
Why?
|
Protein Kinase Inhibitors | 17 | 2023 | 5709 | 0.450 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2014 | 330 | 0.410 |
Why?
|
Biostatistics | 1 | 2014 | 165 | 0.410 |
Why?
|
Cancer Care Facilities | 3 | 2014 | 424 | 0.400 |
Why?
|
Research Design | 8 | 2018 | 6217 | 0.390 |
Why?
|
Quinazolines | 4 | 2016 | 1376 | 0.370 |
Why?
|
Antineoplastic Agents | 17 | 2020 | 13708 | 0.360 |
Why?
|
Sample Size | 1 | 2014 | 851 | 0.360 |
Why?
|
Asparaginase | 4 | 2014 | 240 | 0.350 |
Why?
|
Adenocarcinoma | 11 | 2016 | 6400 | 0.350 |
Why?
|
Metformin | 1 | 2018 | 914 | 0.350 |
Why?
|
Paclitaxel | 12 | 2019 | 1737 | 0.350 |
Why?
|
Prednisone | 19 | 2019 | 1568 | 0.330 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 5 | 2016 | 1766 | 0.310 |
Why?
|
Lymphoma, Non-Hodgkin | 16 | 1999 | 1376 | 0.300 |
Why?
|
Cisplatin | 13 | 2021 | 1661 | 0.290 |
Why?
|
Mutation | 21 | 2023 | 30243 | 0.280 |
Why?
|
Acrylamides | 2 | 2019 | 260 | 0.280 |
Why?
|
Neoplasm Staging | 29 | 2019 | 11249 | 0.280 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2019 | 4083 | 0.270 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2011 | 384 | 0.270 |
Why?
|
Etoposide | 15 | 2020 | 640 | 0.270 |
Why?
|
Spirometry | 3 | 2024 | 928 | 0.260 |
Why?
|
Survival Analysis | 22 | 2020 | 10125 | 0.260 |
Why?
|
Doxorubicin | 19 | 2014 | 2229 | 0.260 |
Why?
|
Humans | 168 | 2024 | 768451 | 0.250 |
Why?
|
Survival Rate | 26 | 2019 | 12875 | 0.240 |
Why?
|
Disease-Free Survival | 18 | 2019 | 6856 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-met | 4 | 2019 | 568 | 0.230 |
Why?
|
Oscillometry | 1 | 2024 | 150 | 0.220 |
Why?
|
Proxy | 1 | 2024 | 151 | 0.220 |
Why?
|
Antibiotics, Antineoplastic | 5 | 2012 | 679 | 0.220 |
Why?
|
Aged, 80 and over | 44 | 2021 | 59680 | 0.220 |
Why?
|
Aniline Compounds | 2 | 2019 | 1094 | 0.210 |
Why?
|
Cystic Fibrosis | 2 | 2022 | 1287 | 0.210 |
Why?
|
Lung Transplantation | 2 | 2024 | 1310 | 0.210 |
Why?
|
Smoke | 1 | 2024 | 236 | 0.210 |
Why?
|
Aged | 78 | 2021 | 171520 | 0.210 |
Why?
|
Neoplasms | 7 | 2022 | 22386 | 0.210 |
Why?
|
Mesothelioma | 2 | 2019 | 811 | 0.210 |
Why?
|
Female | 111 | 2024 | 396943 | 0.200 |
Why?
|
Parents | 4 | 2024 | 3596 | 0.200 |
Why?
|
Middle Aged | 89 | 2023 | 223418 | 0.190 |
Why?
|
Pulmonary Medicine | 1 | 2024 | 223 | 0.190 |
Why?
|
Gastroparesis | 1 | 2024 | 143 | 0.190 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2012 | 89 | 0.190 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2021 | 109 | 0.190 |
Why?
|
Tumor Burden | 6 | 2020 | 1909 | 0.190 |
Why?
|
Male | 101 | 2024 | 364781 | 0.190 |
Why?
|
Pregnancy in Adolescence | 1 | 2022 | 166 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2014 | 9425 | 0.180 |
Why?
|
Adolescent Health Services | 1 | 2022 | 221 | 0.180 |
Why?
|
ras-GRF1 | 1 | 2020 | 26 | 0.180 |
Why?
|
Carcinoma, Small Cell | 4 | 2014 | 420 | 0.170 |
Why?
|
Bullying | 1 | 2023 | 234 | 0.170 |
Why?
|
Proportional Hazards Models | 11 | 2019 | 12561 | 0.170 |
Why?
|
Pregnancy Rate | 1 | 2022 | 655 | 0.160 |
Why?
|
Ovarian Diseases | 1 | 2020 | 137 | 0.160 |
Why?
|
Benzeneacetamides | 1 | 2019 | 36 | 0.160 |
Why?
|
Vascular Surgical Procedures | 4 | 2013 | 1509 | 0.160 |
Why?
|
Prognosis | 25 | 2019 | 30028 | 0.160 |
Why?
|
Cohort Studies | 7 | 2018 | 41797 | 0.160 |
Why?
|
Adult | 75 | 2023 | 223542 | 0.160 |
Why?
|
Treatment Outcome | 31 | 2020 | 65409 | 0.150 |
Why?
|
Receptor, erbB-2 | 4 | 2020 | 2586 | 0.150 |
Why?
|
Anti-Mullerian Hormone | 1 | 2020 | 415 | 0.150 |
Why?
|
Leg | 2 | 2013 | 1089 | 0.150 |
Why?
|
Neoplasms, Glandular and Epithelial | 2 | 2013 | 489 | 0.140 |
Why?
|
Liver Neoplasms | 1 | 2013 | 4362 | 0.140 |
Why?
|
Angioplasty, Balloon | 2 | 2013 | 592 | 0.140 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2020 | 3665 | 0.140 |
Why?
|
Antibodies, Monoclonal | 10 | 2021 | 9263 | 0.140 |
Why?
|
Carcinoma, Large Cell | 3 | 2013 | 114 | 0.140 |
Why?
|
Amenorrhea | 1 | 2020 | 484 | 0.140 |
Why?
|
Neurofibromin 1 | 2 | 2016 | 190 | 0.140 |
Why?
|
Air Pollution, Indoor | 1 | 2024 | 914 | 0.140 |
Why?
|
Cholecalciferol | 1 | 2022 | 557 | 0.140 |
Why?
|
Anilides | 2 | 2016 | 415 | 0.140 |
Why?
|
Adrenal Cortex Hormones | 2 | 2019 | 1891 | 0.140 |
Why?
|
Drug Evaluation | 7 | 1992 | 642 | 0.130 |
Why?
|
Precancerous Conditions | 1 | 2023 | 988 | 0.130 |
Why?
|
Interviews as Topic | 1 | 2024 | 2733 | 0.130 |
Why?
|
Campylobacter Infections | 1 | 2016 | 32 | 0.130 |
Why?
|
Campylobacter | 1 | 2016 | 58 | 0.130 |
Why?
|
Gastroesophageal Reflux | 1 | 2024 | 833 | 0.130 |
Why?
|
Polymerase Chain Reaction | 3 | 2016 | 6091 | 0.130 |
Why?
|
Retrospective Studies | 23 | 2024 | 81834 | 0.130 |
Why?
|
Vincristine | 15 | 2014 | 1039 | 0.130 |
Why?
|
Food Hypersensitivity | 1 | 2023 | 737 | 0.120 |
Why?
|
Gastrointestinal Diseases | 1 | 2024 | 1207 | 0.120 |
Why?
|
Peripheral Vascular Diseases | 2 | 2008 | 489 | 0.120 |
Why?
|
Fellowships and Scholarships | 1 | 2024 | 1134 | 0.120 |
Why?
|
Razoxane | 2 | 2012 | 43 | 0.120 |
Why?
|
Bacteriological Techniques | 1 | 2016 | 277 | 0.120 |
Why?
|
Exons | 3 | 2019 | 2392 | 0.120 |
Why?
|
Ischemia | 2 | 2013 | 1900 | 0.120 |
Why?
|
PTEN Phosphohydrolase | 2 | 2011 | 1119 | 0.120 |
Why?
|
Bone Marrow Transplantation | 10 | 2000 | 2702 | 0.120 |
Why?
|
Remission Induction | 12 | 2016 | 2408 | 0.110 |
Why?
|
DNA, Neoplasm | 2 | 2016 | 1749 | 0.110 |
Why?
|
Risk Assessment | 7 | 2013 | 24311 | 0.110 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2019 | 5342 | 0.110 |
Why?
|
Breast Neoplasms | 4 | 2023 | 21156 | 0.110 |
Why?
|
Drug Administration Schedule | 12 | 2017 | 4861 | 0.110 |
Why?
|
Child | 29 | 2024 | 80863 | 0.110 |
Why?
|
Follow-Up Studies | 20 | 2019 | 39430 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2016 | 1628 | 0.110 |
Why?
|
Gene Deletion | 2 | 2011 | 2674 | 0.110 |
Why?
|
Obesity | 2 | 2013 | 13065 | 0.110 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2013 | 1536 | 0.110 |
Why?
|
Menstrual Cycle | 1 | 2006 | 542 | 0.110 |
Why?
|
Cardiotoxins | 1 | 2012 | 36 | 0.110 |
Why?
|
Self Report | 1 | 2024 | 3771 | 0.110 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2015 | 876 | 0.100 |
Why?
|
Hypertension, Pulmonary | 1 | 2024 | 1605 | 0.100 |
Why?
|
Isotretinoin | 1 | 2014 | 134 | 0.100 |
Why?
|
Lower Extremity | 2 | 2013 | 1214 | 0.100 |
Why?
|
Particulate Matter | 1 | 2024 | 2614 | 0.100 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2016 | 958 | 0.100 |
Why?
|
Planning Techniques | 1 | 1992 | 82 | 0.100 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2012 | 74 | 0.100 |
Why?
|
Comparative Genomic Hybridization | 2 | 2010 | 474 | 0.100 |
Why?
|
Pyridines | 4 | 2016 | 2888 | 0.100 |
Why?
|
Peripheral Arterial Disease | 2 | 2013 | 1299 | 0.100 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2020 | 1614 | 0.100 |
Why?
|
Thiazoles | 1 | 2019 | 1541 | 0.100 |
Why?
|
Cyclophosphamide | 17 | 1998 | 2224 | 0.100 |
Why?
|
Autocrine Communication | 1 | 2012 | 169 | 0.090 |
Why?
|
Anorexia Nervosa | 1 | 2020 | 1363 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2011 | 2465 | 0.090 |
Why?
|
Disease Progression | 10 | 2019 | 13655 | 0.090 |
Why?
|
NAD(P)H Dehydrogenase (Quinone) | 1 | 2011 | 56 | 0.090 |
Why?
|
Intermittent Claudication | 1 | 2013 | 305 | 0.090 |
Why?
|
Sulfotransferases | 1 | 2011 | 150 | 0.090 |
Why?
|
Dexamethasone | 7 | 2013 | 1965 | 0.090 |
Why?
|
Genes, T-Cell Receptor gamma | 1 | 2010 | 16 | 0.090 |
Why?
|
Adolescent | 33 | 2024 | 89168 | 0.090 |
Why?
|
Air Pollutants | 1 | 2024 | 2905 | 0.090 |
Why?
|
Hypertension | 2 | 2010 | 8611 | 0.090 |
Why?
|
Ubiquitins | 1 | 2011 | 367 | 0.090 |
Why?
|
Angioplasty | 1 | 2013 | 357 | 0.090 |
Why?
|
Mutagenesis, Insertional | 1 | 2013 | 662 | 0.090 |
Why?
|
Diagnostic Tests, Routine | 1 | 2016 | 792 | 0.090 |
Why?
|
Program Evaluation | 1 | 2018 | 2508 | 0.090 |
Why?
|
Prospective Studies | 15 | 2024 | 54914 | 0.090 |
Why?
|
Interferon-alpha | 1 | 2014 | 909 | 0.080 |
Why?
|
Hodgkin Disease | 4 | 2008 | 1386 | 0.080 |
Why?
|
Lymphoid Enhancer-Binding Factor 1 | 1 | 2010 | 85 | 0.080 |
Why?
|
Codon, Terminator | 1 | 2010 | 125 | 0.080 |
Why?
|
Air Pollution | 1 | 2023 | 2364 | 0.080 |
Why?
|
Haploinsufficiency | 1 | 2011 | 336 | 0.080 |
Why?
|
Octreotide | 1 | 2010 | 155 | 0.080 |
Why?
|
Fatigue | 4 | 2023 | 1556 | 0.080 |
Why?
|
Immunotherapy | 5 | 2019 | 4728 | 0.080 |
Why?
|
Feces | 1 | 2016 | 1515 | 0.080 |
Why?
|
Bone Density | 1 | 2022 | 3561 | 0.080 |
Why?
|
Smoking Cessation | 1 | 2021 | 2079 | 0.080 |
Why?
|
Child, Preschool | 18 | 2024 | 42623 | 0.080 |
Why?
|
Cardiotonic Agents | 1 | 2012 | 544 | 0.080 |
Why?
|
Decision Making | 2 | 2021 | 3961 | 0.080 |
Why?
|
Pediatrics | 1 | 2024 | 3622 | 0.080 |
Why?
|
Benzimidazoles | 3 | 2020 | 864 | 0.080 |
Why?
|
Immunohistochemistry | 7 | 2018 | 11138 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 6 | 2017 | 6537 | 0.080 |
Why?
|
Behavior | 1 | 2011 | 545 | 0.080 |
Why?
|
Quality of Life | 3 | 2024 | 13497 | 0.080 |
Why?
|
Drug Industry | 1 | 2014 | 793 | 0.070 |
Why?
|
Biomedical Research | 1 | 2023 | 3463 | 0.070 |
Why?
|
Oncogenes | 1 | 2013 | 1235 | 0.070 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2019 | 300 | 0.070 |
Why?
|
HLA Antigens | 5 | 2000 | 1338 | 0.070 |
Why?
|
Thymus Neoplasms | 1 | 2010 | 278 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 1409 | 0.070 |
Why?
|
Lymphoma, Follicular | 1 | 2011 | 460 | 0.070 |
Why?
|
Embryonic Development | 1 | 2012 | 722 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2017 | 3550 | 0.070 |
Why?
|
Lung | 5 | 2024 | 10090 | 0.070 |
Why?
|
Molecular Targeted Therapy | 2 | 2015 | 2834 | 0.070 |
Why?
|
Neurofibromatosis 1 | 1 | 2012 | 561 | 0.070 |
Why?
|
Adhesins, Bacterial | 1 | 2007 | 120 | 0.070 |
Why?
|
Fimbriae Proteins | 1 | 2007 | 133 | 0.070 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2022 | 2444 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 2 | 2021 | 2819 | 0.070 |
Why?
|
Cytarabine | 7 | 2014 | 697 | 0.070 |
Why?
|
Troponin T | 1 | 2012 | 787 | 0.070 |
Why?
|
Thalidomide | 1 | 2012 | 885 | 0.070 |
Why?
|
Cell Proliferation | 4 | 2020 | 10494 | 0.070 |
Why?
|
Aortic Rupture | 1 | 2009 | 322 | 0.070 |
Why?
|
Methotrexate | 10 | 2014 | 1722 | 0.070 |
Why?
|
Age Factors | 11 | 2016 | 18478 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2010 | 727 | 0.070 |
Why?
|
Bacterial Adhesion | 1 | 2007 | 305 | 0.070 |
Why?
|
Continuity of Patient Care | 1 | 2013 | 1076 | 0.070 |
Why?
|
Autoimmune Diseases | 1 | 2018 | 2260 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2011 | 998 | 0.060 |
Why?
|
Mutation, Missense | 2 | 2013 | 2594 | 0.060 |
Why?
|
Bleomycin | 9 | 1994 | 495 | 0.060 |
Why?
|
Saphenous Vein | 1 | 2008 | 519 | 0.060 |
Why?
|
Sequence Deletion | 1 | 2010 | 1497 | 0.060 |
Why?
|
Graft Occlusion, Vascular | 1 | 2008 | 538 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 3543 | 0.060 |
Why?
|
Smoking | 3 | 2021 | 9099 | 0.060 |
Why?
|
Neoplasm Metastasis | 4 | 2019 | 4931 | 0.060 |
Why?
|
Burkitt Lymphoma | 1 | 2007 | 336 | 0.060 |
Why?
|
Time Factors | 13 | 2013 | 40271 | 0.060 |
Why?
|
Heart Ventricles | 2 | 2012 | 3839 | 0.060 |
Why?
|
Risk Factors | 13 | 2024 | 74915 | 0.060 |
Why?
|
Germ-Line Mutation | 2 | 2023 | 1884 | 0.060 |
Why?
|
Palliative Care | 1 | 2019 | 3644 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2013 | 2884 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2014 | 2785 | 0.060 |
Why?
|
Zebrafish | 2 | 2012 | 3038 | 0.050 |
Why?
|
Ventricular Function, Left | 3 | 2012 | 3941 | 0.050 |
Why?
|
Volatile Organic Compounds | 1 | 2024 | 86 | 0.050 |
Why?
|
Camptothecin | 3 | 2013 | 594 | 0.050 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 1993 | 1427 | 0.050 |
Why?
|
Cardiomyopathies | 2 | 2012 | 2056 | 0.050 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2012 | 1751 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2020 | 7895 | 0.050 |
Why?
|
Young Adult | 10 | 2022 | 60045 | 0.050 |
Why?
|
Genotype | 5 | 2016 | 13047 | 0.050 |
Why?
|
Topotecan | 2 | 2013 | 131 | 0.050 |
Why?
|
Models, Statistical | 2 | 2006 | 5103 | 0.050 |
Why?
|
Echocardiography | 2 | 2012 | 5043 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 5 | 2020 | 20762 | 0.050 |
Why?
|
Treatment Failure | 4 | 2015 | 2656 | 0.050 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2012 | 2847 | 0.050 |
Why?
|
Topoisomerase I Inhibitors | 2 | 2013 | 70 | 0.050 |
Why?
|
Pancreatitis | 1 | 2009 | 1087 | 0.050 |
Why?
|
Gene Frequency | 5 | 2016 | 3615 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 3734 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7451 | 0.050 |
Why?
|
Streptococcus pneumoniae | 1 | 2007 | 765 | 0.050 |
Why?
|
Neoplasm Proteins | 2 | 2010 | 3611 | 0.050 |
Why?
|
Health Status Disparities | 1 | 2013 | 1876 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2016 | 14728 | 0.050 |
Why?
|
Nitrogen Dioxide | 1 | 2024 | 527 | 0.050 |
Why?
|
Massachusetts | 3 | 2024 | 8908 | 0.050 |
Why?
|
ras Proteins | 2 | 2020 | 1058 | 0.050 |
Why?
|
Causality | 1 | 2007 | 1255 | 0.050 |
Why?
|
Vital Capacity | 1 | 2024 | 984 | 0.050 |
Why?
|
Neoplasms, Second Primary | 2 | 2008 | 1062 | 0.050 |
Why?
|
Boston | 1 | 2014 | 9361 | 0.050 |
Why?
|
Arsenicals | 1 | 2001 | 117 | 0.050 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2013 | 2040 | 0.050 |
Why?
|
Pericytes | 1 | 2024 | 299 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2020 | 3619 | 0.050 |
Why?
|
Biometry | 1 | 1984 | 565 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2015 | 10358 | 0.050 |
Why?
|
Hospitals, Urban | 1 | 2022 | 501 | 0.040 |
Why?
|
Sirolimus | 1 | 2007 | 1542 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2011 | 2987 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2011 | 5803 | 0.040 |
Why?
|
Recurrence | 9 | 2011 | 8510 | 0.040 |
Why?
|
Cell Line, Tumor | 5 | 2019 | 17149 | 0.040 |
Why?
|
Infant, Newborn | 5 | 2024 | 26395 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2017 | 10784 | 0.040 |
Why?
|
Pentoxifylline | 1 | 2000 | 53 | 0.040 |
Why?
|
Oxides | 1 | 2001 | 403 | 0.040 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2001 | 249 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2022 | 5308 | 0.040 |
Why?
|
Data Collection | 2 | 2011 | 3329 | 0.040 |
Why?
|
Family Planning Services | 1 | 2022 | 276 | 0.040 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2009 | 1252 | 0.040 |
Why?
|
Brain Neoplasms | 3 | 2019 | 9182 | 0.040 |
Why?
|
Patient Selection | 3 | 2019 | 4266 | 0.040 |
Why?
|
Menogaril | 1 | 1999 | 4 | 0.040 |
Why?
|
Ovarian Neoplasms | 2 | 2013 | 4906 | 0.040 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2009 | 1460 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2012 | 5152 | 0.040 |
Why?
|
Forced Expiratory Volume | 1 | 2024 | 1820 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 3207 | 0.040 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2012 | 3623 | 0.040 |
Why?
|
Chronic Disease | 5 | 2022 | 9382 | 0.040 |
Why?
|
Heart | 1 | 2012 | 4451 | 0.040 |
Why?
|
Research Subjects | 1 | 2020 | 249 | 0.040 |
Why?
|
Radiation Pneumonitis | 1 | 2019 | 103 | 0.040 |
Why?
|
Seasons | 1 | 2024 | 1526 | 0.040 |
Why?
|
Infant | 11 | 2016 | 36497 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2021 | 467 | 0.040 |
Why?
|
Sex Factors | 5 | 2013 | 10647 | 0.040 |
Why?
|
Spheroids, Cellular | 1 | 2020 | 332 | 0.040 |
Why?
|
Environmental Monitoring | 1 | 2024 | 1464 | 0.040 |
Why?
|
Body Mass Index | 2 | 2013 | 13030 | 0.040 |
Why?
|
Placebos | 2 | 2018 | 1668 | 0.040 |
Why?
|
Allosteric Regulation | 1 | 2019 | 424 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2013 | 3412 | 0.040 |
Why?
|
Limb Salvage | 2 | 2013 | 489 | 0.040 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2012 | 656 | 0.040 |
Why?
|
Venous Thromboembolism | 1 | 2011 | 1884 | 0.040 |
Why?
|
NIH 3T3 Cells | 1 | 2019 | 669 | 0.040 |
Why?
|
Logistic Models | 4 | 2016 | 13324 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2022 | 20231 | 0.030 |
Why?
|
Cyclosporins | 2 | 1988 | 216 | 0.030 |
Why?
|
Radionuclide Ventriculography | 1 | 1996 | 40 | 0.030 |
Why?
|
Signal Transduction | 4 | 2016 | 23638 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2019 | 4780 | 0.030 |
Why?
|
Cytokines | 1 | 2011 | 7449 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2016 | 2434 | 0.030 |
Why?
|
Thrombocytopenia | 4 | 2015 | 1183 | 0.030 |
Why?
|
Graft vs Host Disease | 5 | 2000 | 3042 | 0.030 |
Why?
|
Thallium Radioisotopes | 1 | 1996 | 139 | 0.030 |
Why?
|
Dipyridamole | 1 | 1996 | 143 | 0.030 |
Why?
|
Cell Survival | 2 | 2019 | 5801 | 0.030 |
Why?
|
Absorptiometry, Photon | 1 | 2022 | 1749 | 0.030 |
Why?
|
Water | 1 | 2022 | 1421 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 4586 | 0.030 |
Why?
|
Mice | 6 | 2024 | 82045 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1839 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2011 | 8635 | 0.030 |
Why?
|
RNA, Viral | 1 | 2023 | 2865 | 0.030 |
Why?
|
Bone Marrow | 3 | 2022 | 2929 | 0.030 |
Why?
|
Vascular Patency | 2 | 2008 | 916 | 0.030 |
Why?
|
Leucovorin | 6 | 1994 | 643 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2633 | 0.030 |
Why?
|
DNA Mutational Analysis | 2 | 2013 | 4120 | 0.030 |
Why?
|
Lymphoma | 3 | 1990 | 1907 | 0.030 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2020 | 716 | 0.030 |
Why?
|
Pleural Neoplasms | 1 | 2019 | 612 | 0.030 |
Why?
|
Quinolines | 1 | 2020 | 769 | 0.030 |
Why?
|
Multivariate Analysis | 5 | 2013 | 12096 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2014 | 70 | 0.030 |
Why?
|
Predictive Value of Tests | 4 | 2016 | 15460 | 0.030 |
Why?
|
Blood Pressure | 1 | 2010 | 8538 | 0.030 |
Why?
|
Incidence | 3 | 2024 | 21552 | 0.030 |
Why?
|
Immune System | 1 | 2019 | 801 | 0.030 |
Why?
|
Leukopenia | 1 | 2014 | 214 | 0.030 |
Why?
|
Pyrazoles | 2 | 2016 | 2024 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2016 | 2964 | 0.030 |
Why?
|
Animals | 8 | 2024 | 169418 | 0.030 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2013 | 94 | 0.030 |
Why?
|
United States | 8 | 2019 | 73121 | 0.030 |
Why?
|
Vitamins | 1 | 2022 | 1638 | 0.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2011 | 5709 | 0.030 |
Why?
|
Lymphoid Tissue | 1 | 1995 | 446 | 0.030 |
Why?
|
Base Sequence | 2 | 2016 | 12428 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2020 | 1489 | 0.030 |
Why?
|
Capsules | 1 | 2013 | 193 | 0.030 |
Why?
|
Tablets | 1 | 2013 | 149 | 0.030 |
Why?
|
Anemia, Aplastic | 2 | 1986 | 231 | 0.030 |
Why?
|
Melanophores | 1 | 2012 | 16 | 0.030 |
Why?
|
Genes, erbB-1 | 1 | 2013 | 163 | 0.030 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2013 | 96 | 0.030 |
Why?
|
Lumbar Vertebrae | 1 | 2022 | 1885 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2015 | 637 | 0.030 |
Why?
|
Karyotyping | 1 | 2014 | 1173 | 0.030 |
Why?
|
Immunoassay | 1 | 2016 | 746 | 0.030 |
Why?
|
DNA Repair | 1 | 2021 | 2051 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6135 | 0.020 |
Why?
|
Vitamin D Deficiency | 1 | 2022 | 1389 | 0.020 |
Why?
|
Sulfatases | 1 | 2011 | 44 | 0.020 |
Why?
|
Radiotherapy | 3 | 2011 | 1510 | 0.020 |
Why?
|
Whole-Body Irradiation | 4 | 2000 | 434 | 0.020 |
Why?
|
Blotting, Western | 2 | 2011 | 5042 | 0.020 |
Why?
|
Cryoultramicrotomy | 1 | 2011 | 16 | 0.020 |
Why?
|
Gastric Mucosa | 1 | 1995 | 603 | 0.020 |
Why?
|
Patient Participation | 1 | 2021 | 1450 | 0.020 |
Why?
|
Combined Modality Therapy | 6 | 2011 | 8559 | 0.020 |
Why?
|
Observer Variation | 1 | 2018 | 2622 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2024 | 2411 | 0.020 |
Why?
|
Endocardium | 1 | 1992 | 249 | 0.020 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2011 | 108 | 0.020 |
Why?
|
Schwann Cells | 1 | 2012 | 196 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 16029 | 0.020 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2012 | 259 | 0.020 |
Why?
|
Arabinonucleotides | 1 | 1990 | 5 | 0.020 |
Why?
|
Vidarabine Phosphate | 1 | 1990 | 11 | 0.020 |
Why?
|
Internationality | 1 | 2006 | 1007 | 0.020 |
Why?
|
Genes, Immunoglobulin | 1 | 2011 | 286 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2024 | 3586 | 0.020 |
Why?
|
Osteonecrosis | 1 | 2013 | 230 | 0.020 |
Why?
|
Transplantation Conditioning | 1 | 1998 | 1598 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 2013 | 13452 | 0.020 |
Why?
|
Hepatocyte Growth Factor | 1 | 2012 | 270 | 0.020 |
Why?
|
Infusions, Intravenous | 2 | 2012 | 2228 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 26351 | 0.020 |
Why?
|
Luminescent Measurements | 1 | 2012 | 342 | 0.020 |
Why?
|
Sampling Studies | 1 | 1992 | 617 | 0.020 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 1996 | 857 | 0.020 |
Why?
|
Leukemia | 3 | 1989 | 1527 | 0.020 |
Why?
|
Nomograms | 1 | 2012 | 236 | 0.020 |
Why?
|
Phthalazines | 1 | 2013 | 396 | 0.020 |
Why?
|
Pneumonectomy | 1 | 2017 | 1159 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 2015 | 1139 | 0.020 |
Why?
|
Larva | 1 | 2012 | 514 | 0.020 |
Why?
|
Nausea | 1 | 2013 | 682 | 0.020 |
Why?
|
HLA-D Antigens | 2 | 1987 | 130 | 0.020 |
Why?
|
Probability | 2 | 1993 | 2483 | 0.020 |
Why?
|
Apoptosis | 2 | 2020 | 9526 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3906 | 0.020 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 665 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2013 | 17647 | 0.020 |
Why?
|
Multicenter Studies as Topic | 2 | 1992 | 1727 | 0.020 |
Why?
|
Taxoids | 1 | 2013 | 669 | 0.020 |
Why?
|
Colitis, Ulcerative | 1 | 2022 | 1930 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2024 | 4533 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 2863 | 0.020 |
Why?
|
Zinc Fingers | 1 | 2011 | 577 | 0.020 |
Why?
|
Crohn Disease | 1 | 2022 | 2293 | 0.020 |
Why?
|
Hyperplasia | 1 | 2012 | 1154 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 906 | 0.020 |
Why?
|
Withholding Treatment | 1 | 2013 | 621 | 0.020 |
Why?
|
Alleles | 2 | 2010 | 6890 | 0.020 |
Why?
|
Mycosis Fungoides | 1 | 1990 | 170 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2022 | 3445 | 0.020 |
Why?
|
Ligands | 1 | 2015 | 3281 | 0.020 |
Why?
|
Medication Adherence | 1 | 2020 | 2190 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2013 | 2751 | 0.020 |
Why?
|
Epidemiologic Methods | 2 | 2011 | 1337 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2013 | 888 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2023 | 4049 | 0.020 |
Why?
|
Curriculum | 1 | 2022 | 3778 | 0.020 |
Why?
|
HLA-DR Antigens | 2 | 1987 | 607 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 2013 | 1145 | 0.020 |
Why?
|
Oligodendroglia | 1 | 2012 | 538 | 0.020 |
Why?
|
Myelin Sheath | 1 | 2012 | 653 | 0.020 |
Why?
|
SEER Program | 1 | 2013 | 1476 | 0.020 |
Why?
|
Vitamin D | 1 | 2022 | 3311 | 0.020 |
Why?
|
Pain | 1 | 2023 | 5096 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2018 | 12450 | 0.020 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1226 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2013 | 1794 | 0.020 |
Why?
|
Area Under Curve | 1 | 2012 | 1640 | 0.020 |
Why?
|
Databases as Topic | 1 | 2009 | 475 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2024 | 3837 | 0.020 |
Why?
|
Hospital Mortality | 2 | 2013 | 5371 | 0.020 |
Why?
|
Reoperation | 2 | 2008 | 4342 | 0.020 |
Why?
|
Microscopy, Immunoelectron | 1 | 2007 | 317 | 0.020 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2009 | 595 | 0.020 |
Why?
|
E-Selectin | 1 | 2009 | 578 | 0.020 |
Why?
|
Gene Rearrangement, T-Lymphocyte | 1 | 2007 | 111 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2011 | 1906 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3438 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1855 | 0.020 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2009 | 692 | 0.020 |
Why?
|
Living Donors | 1 | 2011 | 651 | 0.020 |
Why?
|
DNA Primers | 1 | 2011 | 2826 | 0.020 |
Why?
|
Azathioprine | 1 | 1988 | 354 | 0.020 |
Why?
|
Leprosy | 1 | 1987 | 126 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14766 | 0.020 |
Why?
|
Tamoxifen | 1 | 2011 | 968 | 0.020 |
Why?
|
Multigene Family | 1 | 2010 | 1081 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1990 | 647 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2019 | 9558 | 0.020 |
Why?
|
Diarrhea | 1 | 2013 | 1320 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2012 | 3594 | 0.020 |
Why?
|
Animals, Genetically Modified | 1 | 2011 | 1563 | 0.020 |
Why?
|
Family Health | 1 | 2011 | 1256 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 2011 | 4175 | 0.020 |
Why?
|
Esophagus | 1 | 2012 | 1045 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2016 | 2072 | 0.020 |
Why?
|
Translocation, Genetic | 1 | 2011 | 1395 | 0.020 |
Why?
|
Zebrafish Proteins | 1 | 2012 | 1019 | 0.020 |
Why?
|
Thromboembolism | 1 | 2012 | 1006 | 0.020 |
Why?
|
Mice, Nude | 1 | 2011 | 3635 | 0.020 |
Why?
|
Administration, Oral | 1 | 2013 | 4041 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1795 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2013 | 3637 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2008 | 1103 | 0.020 |
Why?
|
Pilot Projects | 2 | 2001 | 8730 | 0.020 |
Why?
|
Receptors, Estrogen | 1 | 2013 | 2243 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2011 | 1444 | 0.020 |
Why?
|
Age Distribution | 1 | 2011 | 2881 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2007 | 15880 | 0.010 |
Why?
|
Chimera | 1 | 1986 | 454 | 0.010 |
Why?
|
Kinetics | 1 | 2012 | 6348 | 0.010 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 3246 | 0.010 |
Why?
|
Ventricular Remodeling | 1 | 2012 | 1280 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5367 | 0.010 |
Why?
|
World Health Organization | 1 | 2010 | 1328 | 0.010 |
Why?
|
Pandemics | 1 | 2024 | 8753 | 0.010 |
Why?
|
Intestinal Mucosa | 1 | 1995 | 3048 | 0.010 |
Why?
|
Tachycardia, Ventricular | 1 | 1992 | 1309 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2015 | 2896 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2016 | 4534 | 0.010 |
Why?
|
Up-Regulation | 1 | 2012 | 4138 | 0.010 |
Why?
|
RNA Interference | 1 | 2011 | 2832 | 0.010 |
Why?
|
Learning | 1 | 2012 | 1762 | 0.010 |
Why?
|
Piperazines | 1 | 2013 | 2546 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3437 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 1985 | 11206 | 0.010 |
Why?
|
Motor Activity | 1 | 2012 | 2722 | 0.010 |
Why?
|
Antilymphocyte Serum | 1 | 1984 | 491 | 0.010 |
Why?
|
Patient Compliance | 1 | 2012 | 2696 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2007 | 1014 | 0.010 |
Why?
|
Evaluation Studies as Topic | 2 | 2000 | 1629 | 0.010 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 2062 | 0.010 |
Why?
|
Coronary Disease | 1 | 1996 | 5926 | 0.010 |
Why?
|
Stents | 1 | 2013 | 3204 | 0.010 |
Why?
|
Hospitals, Special | 1 | 1982 | 90 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2012 | 22365 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3794 | 0.010 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2007 | 1139 | 0.010 |
Why?
|
Odds Ratio | 1 | 2013 | 9687 | 0.010 |
Why?
|
Transplantation, Autologous | 2 | 1998 | 2126 | 0.010 |
Why?
|
Pregnancy | 1 | 2022 | 30179 | 0.010 |
Why?
|
Fractures, Bone | 1 | 2013 | 2063 | 0.010 |
Why?
|
Escherichia coli | 1 | 2013 | 4220 | 0.010 |
Why?
|
Diabetes Complications | 1 | 2007 | 1322 | 0.010 |
Why?
|
Leukocytosis | 1 | 2001 | 251 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2012 | 3854 | 0.010 |
Why?
|
Critical Illness | 1 | 2013 | 2754 | 0.010 |
Why?
|
Transplantation, Homologous | 3 | 2000 | 4834 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 18048 | 0.010 |
Why?
|
Genetic Diseases, Inborn | 1 | 1984 | 604 | 0.010 |
Why?
|
Radiotherapy Dosage | 2 | 1998 | 2925 | 0.010 |
Why?
|
Stem Cells | 1 | 2012 | 3538 | 0.010 |
Why?
|
Risk | 3 | 1987 | 9642 | 0.010 |
Why?
|
Antigens, CD | 1 | 2010 | 4029 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 1994 | 5808 | 0.010 |
Why?
|
Population Surveillance | 1 | 2009 | 2601 | 0.010 |
Why?
|
Nuclear Family | 1 | 2000 | 311 | 0.010 |
Why?
|
Genetic Linkage | 1 | 1984 | 2342 | 0.010 |
Why?
|
Platelet Count | 1 | 2001 | 786 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2009 | 3520 | 0.010 |
Why?
|
Carmustine | 1 | 1998 | 137 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2007 | 2568 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2007 | 6527 | 0.010 |
Why?
|
Prevalence | 1 | 2015 | 15880 | 0.010 |
Why?
|
DNA Methylation | 1 | 2011 | 4421 | 0.010 |
Why?
|
Korea | 2 | 1987 | 98 | 0.010 |
Why?
|
Patient Dropouts | 1 | 1999 | 411 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2014 | 15965 | 0.010 |
Why?
|
Length of Stay | 1 | 2009 | 6521 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2007 | 3697 | 0.010 |
Why?
|
Protein Binding | 1 | 2007 | 9376 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 1996 | 11515 | 0.010 |
Why?
|
Anticoagulants | 1 | 2011 | 4840 | 0.010 |
Why?
|
Syndrome | 1 | 2001 | 3278 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2012 | 22293 | 0.010 |
Why?
|
Behavior Therapy | 1 | 2000 | 885 | 0.010 |
Why?
|
Cause of Death | 2 | 1998 | 3727 | 0.010 |
Why?
|
Aging | 1 | 1993 | 8761 | 0.010 |
Why?
|
Clinical Competence | 1 | 2009 | 4841 | 0.010 |
Why?
|
Levamisole | 1 | 1993 | 36 | 0.010 |
Why?
|
Graft Rejection | 1 | 1986 | 4505 | 0.010 |
Why?
|
Mathematics | 1 | 1993 | 704 | 0.010 |
Why?
|
Ki-67 Antigen | 1 | 1994 | 631 | 0.010 |
Why?
|
Pulmonary Wedge Pressure | 1 | 1992 | 278 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 1985 | 7863 | 0.010 |
Why?
|
Salvage Therapy | 1 | 1998 | 1277 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 2001 | 1668 | 0.010 |
Why?
|
Heart Failure | 1 | 2015 | 11857 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2010 | 12774 | 0.010 |
Why?
|
Tissue Donors | 1 | 2000 | 2377 | 0.010 |
Why?
|
BCG Vaccine | 1 | 1993 | 383 | 0.010 |
Why?
|
Anthracenes | 1 | 1989 | 83 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 2279 | 0.010 |
Why?
|
Mitoguazone | 1 | 1989 | 11 | 0.010 |
Why?
|
Vinblastine | 1 | 1991 | 488 | 0.010 |
Why?
|
Mitoxantrone | 1 | 1989 | 148 | 0.010 |
Why?
|
Southwestern United States | 1 | 1989 | 39 | 0.010 |
Why?
|
L-Lactate Dehydrogenase | 1 | 1990 | 413 | 0.010 |
Why?
|
Drug Therapy, Combination | 2 | 1988 | 6320 | 0.000 |
Why?
|
Electrocardiography | 1 | 2001 | 6410 | 0.000 |
Why?
|
Hematologic Neoplasms | 1 | 2000 | 1905 | 0.000 |
Why?
|
Lepromin | 1 | 1987 | 8 | 0.000 |
Why?
|
Analysis of Variance | 1 | 1996 | 6242 | 0.000 |
Why?
|
Regression Analysis | 2 | 1989 | 6353 | 0.000 |
Why?
|
Cardiopulmonary Bypass | 1 | 1992 | 1097 | 0.000 |
Why?
|
Lactoylglutathione Lyase | 1 | 1986 | 7 | 0.000 |
Why?
|
Complement C2 | 1 | 1986 | 45 | 0.000 |
Why?
|
Preoperative Care | 1 | 1996 | 2257 | 0.000 |
Why?
|
Acute Disease | 2 | 1989 | 7246 | 0.000 |
Why?
|
Cell Division | 1 | 1994 | 4479 | 0.000 |
Why?
|
HLA-DQ Antigens | 1 | 1986 | 190 | 0.000 |
Why?
|
Leukocyte Count | 1 | 1990 | 1604 | 0.000 |
Why?
|
Complement C4 | 1 | 1986 | 216 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 1984 | 10273 | 0.000 |
Why?
|
Oxymetholone | 1 | 1984 | 8 | 0.000 |
Why?
|
Procarbazine | 1 | 1983 | 172 | 0.000 |
Why?
|
Colony-Forming Units Assay | 1 | 1984 | 352 | 0.000 |
Why?
|
Random Allocation | 1 | 1984 | 2399 | 0.000 |
Why?
|
Disease Susceptibility | 1 | 1987 | 1797 | 0.000 |
Why?
|
Postoperative Period | 1 | 1985 | 1833 | 0.000 |
Why?
|
Blood Transfusion | 1 | 1986 | 1308 | 0.000 |
Why?
|
Hematopoiesis | 1 | 1986 | 2058 | 0.000 |
Why?
|
Androgens | 1 | 1984 | 1285 | 0.000 |
Why?
|
Carcinoma in Situ | 1 | 1982 | 791 | 0.000 |
Why?
|
Glucocorticoids | 1 | 1985 | 2170 | 0.000 |
Why?
|
Genetic Testing | 1 | 1986 | 3586 | 0.000 |
Why?
|
Phenotype | 1 | 1989 | 16712 | 0.000 |
Why?
|